A number of immunohistological studies have shown high levels of MCL-1 and BCL-XL in prostate cancer, but BCL-2 appears to be expressed at lower levels, with more interstudy variability [47,176,177,178,179,180,181,182,183,184]. The gene discussed is BCL2L1; the disease is prostate carcinoma.